Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
24 participants
INTERVENTIONAL
2025-06-30
2025-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia
NCT06762548
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
NCT06648850
Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia
NCT03831334
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
NCT06501924
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
NCT03315689
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phenylephrine
Topical Phenylephrine
Phenylephrine
Topical Phenylephrine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Phenylephrine
Topical Phenylephrine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI: 18-30 kg/m²
* Fitzpatrick Skin Types I-IV (to standardize absorption risk)
* Scalp free from irritation, dermatologic disease, or damage
* Able to refrain from using other topical scalp products
Exclusion Criteria
* Scalp infections, wounds, or significant hair loss
* Recent use of medications that interfere with CYP enzymes or adrenergic systems
* Known sensitivity to phenylephrine or ethanol
* Positive drug screen or abnormal ECG at screening
18 Years
55 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daniel Alain, Inc.
UNKNOWN
Follea International Limited
INDUSTRY
Applied Biology, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andy Goren, MD
Role: STUDY_DIRECTOR
University of Rome G. Marconi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Rome ("G. Marconi")
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Fahl WE. Complete prevention of radiation-induced dermatitis using topical adrenergic vasoconstrictors. Arch Dermatol Res. 2016 Dec;308(10):751-757. doi: 10.1007/s00403-016-1691-2. Epub 2016 Oct 4.
Soref CM, Fahl WE. A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer. 2015 Jan 1;136(1):195-203. doi: 10.1002/ijc.28961. Epub 2014 May 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA-PK-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.